Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
2013 ◽
Vol 34
(1)
◽
pp. 9-17
◽
2017 ◽
Vol 34
(1)
◽
pp. 55-63
◽